Fig. 3
From: Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine
Immunogenicity of the GAP vaccine. The parasite-specific antibody response was determined by collecting blood samples and measuring anti-MSP2 IgG over the course of the study in each subject (A). The cell-mediated immune response was determined by measuring the frequency of activated (PD-1+ ICOS+) CD4+ Tfh cells (B) and activated (CD38hi HLA-DR+) Th1 cells (C) in peripheral blood mononuclear cells over the course of the study in each subject. CD4+ T cell subsets were identified in B and C as indicated in Additional File 2: Figure S1. The cell-mediated immune response was not determined for cohort 4 (subject 7 and subject 8).